Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has scheduled its Q4 2024 financial results announcement for March 31, 2025, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can access the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live webcast will be available on the Curis website's investor section, with a replay accessible at www.curis.com.
Curis (NASDAQ: CRIS) presented additional data from the TakeAim Leukemia study of emavusertib in relapsed/refractory Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The updated results include data from 21 patients with FLT3 mutation treated at the Recommended Phase 2 Dose of 300 mg BID.
Among 19 response-evaluable patients, 10 showed objective responses: 6 complete remissions (CR), 2 CR with incomplete/partial hematological recovery, and 2 morphologic leukemia-free state. Prior therapies of responders included Venetoclax, HMA, and FLT3i. Two patients proceeded to allogenic stem cell transplantation, with 7 of 10 responses observed at first assessment.
Curis Inc (NASDAQ: CRIS) reported Q3 2024 financial results with a net loss of $10.1 million ($1.70 per share), compared to $12.2 million in Q3 2023. Revenues were $2.9 million, primarily from Erivedge® royalties. The company completed a registered direct offering with net proceeds of $10.8 million. Clinical progress includes promising data from the TakeAim Lymphoma study, showing 3 complete responses and 1 unconfirmed complete response in PCNSL patients. Cash position stands at $31.6 million, expected to fund operations into mid-2025.
Curis (NASDAQ: CRIS) has announced it will release its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. The biotechnology company, which focuses on developing emavusertib (CA-4948), an oral IRAK4 inhibitor, will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the investor section of the Curis website.
Curis (NASDAQ: CRIS) has announced a $12.1 million financing through a registered direct offering and concurrent private placement. The company will issue 2,398,414 shares of common stock and unregistered warrants to purchase an equal number of shares. The warrants have an exercise price of $4.92 per share, are immediately exercisable, and expire in five years. The combined purchase price is $5.045 per share and warrant. The proceeds will fund research, development, working capital, and general corporate purposes. The offering is expected to close around October 30, 2024.
Curis, Inc. (NASDAQ: CRIS) announces the 3rd Annual Symposium on IRAK4 in Cancer, scheduled for September 26, 2024. The virtual event, hosted by Dr. Eric S. Winer and Dr. Grzegorz S. Nowakowski, will focus on IRAK4 as an emerging target in treating hematologic malignancies and solid tumors. The symposium will feature updated data for 10 evaluable R/R PCNSL patients as of July 10, 2024. Curis aims to enroll 15-20 patients in the PCNSL study by year-end.
The event will bring together experts to discuss the potential of IRAK4 inhibition in cancer, including current clinical studies of emavusertib (CA-4948), Curis's orally available, small molecule IRAK4 inhibitor. Presentations will cover the biology of the IRAK4 pathway and its inhibition in cancer therapy development. The symposium is free and open to the public, offering insights into this promising area of oncology research.
Curis Inc (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. James Dentzer, President and CEO of Curis, will engage in a fireside chat on September 17, 2024, at 4:15 PM ET.
The event will be accessible via webcast through the Cantor link and on the Curis website in the Investors section. This participation underscores Curis's commitment to engaging with the investment community and showcasing its progress in developing innovative therapies for cancer treatment.
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in two upcoming healthcare conferences in September 2024. James Dentzer, President and CEO, will represent Curis at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11): Company presentation on Sept. 11 at 1:00 pm ET.
2. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19): Fireside chat on Sept. 17 at 3:05 pm ET.
Webcasts for both presentations will be available on the Curis website in the 'Investors' section, providing investors with opportunities to gain insights into the company's progress and strategy.
Curis Inc. (NASDAQ: CRIS) reported Q2 2024 financial results and operational updates. Key highlights include:
1. European Commission granted Orphan Drug Designation to emavusertib for PCNSL treatment.
2. Initial data for 15-20 R/R PCNSL patients expected by late 2024.
3. Positive preliminary data in R/R AML patients with FLT3 and SF mutations.
4. Q2 2024 net loss of $11.8 million ($2.03 per share) vs $12.0 million ($2.47 per share) in Q2 2023.
5. Revenues increased to $2.5 million in Q2 2024 from $2.2 million in Q2 2023.
6. Cash position of $28.4 million as of June 30, 2024, expected to fund operations into Q1 2025.
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its plans to release second quarter 2024 financial and operating results on August 1, 2024, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live audio webcast will be available on the investor section of the Curis website, with a replay accessible later at www.curis.com.